Deng Qiong, Pan Shenzhen, Du Fangzhou, Sang Hongfei, Cai Zhixin, Xu Xiaoyu, Wei Qian, Yu Shuang, Zhang Jingzhong, Li Chenglong
Department of Vascular Surgery, The Second Affiliated Hospital of Soochow University, Suzhou 215000, China.
School of Biomedical Engineering (Suzhou), Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230026, China.
Bioengineering (Basel). 2024 Dec 9;11(12):1244. doi: 10.3390/bioengineering11121244.
Mesenchymal stem cells (MSCs) have been introduced as a promising treatment for diabetic wounds. The effects of stem cell therapy are thought to be caused by bioactive molecules secreted by stem cells. Stem cell-based gene therapies can target bioactive molecules. Therefore, treatment using conditioned medium (CM) derived from genetically engineered stem cells has been proposed as an alternative option for diabetic ulcer care.
MSCs derived from human umbilical cords were obtained and engineered to overexpress the angiogenin-1 gene (MSCs) through plasmid transfection. This study extracted conditioned medium from MSCs (MSC-CM) or MSCs(MSC-CM) for wound treatment applications. Via in vitro experiments, the proangiogenic effects of MSC-CM were assessed via the migration and tube formation of human umbilical vein endothelial cells (HUVECs). Furthermore, the efficacy of MSC-CM in promoting wound healing, re-epithelialization, hair follicle, and angiogenesis was evaluated via a diabetic mouse skin defect model.
In vitro assays demonstrated that MSC-CM significantly enhanced HUVECs' functions, including migration and tube formation. In vivo assays revealed that MSC-CM exhibited notable advancements in healing speed, re-epithelialization, hair follicle, and angiogenesis.
These results indicate that MSC-CM can promote wound healing in diabetic mice and make the vascular structure in regenerated tissues more stable without inducing tissue fibrosis, providing a new therapeutic strategy for treating diabetic skin wounds. This provides a valuable theoretical basis for further research on regenerative medicine and cell therapy.
间充质干细胞(MSCs)已被引入作为糖尿病伤口的一种有前景的治疗方法。干细胞疗法的效果被认为是由干细胞分泌的生物活性分子所引起的。基于干细胞的基因疗法可以靶向生物活性分子。因此,有人提出使用源自基因工程干细胞的条件培养基(CM)进行治疗,作为糖尿病溃疡护理的一种替代选择。
获取源自人脐带的间充质干细胞,并通过质粒转染对其进行工程改造,使其过表达血管生成素-1基因(MSCs)。本研究从MSCs(MSC-CM)或MSCs(MSC-CM)中提取条件培养基用于伤口治疗应用。通过体外实验,通过人脐静脉内皮细胞(HUVECs)的迁移和管形成来评估MSC-CM的促血管生成作用。此外,通过糖尿病小鼠皮肤缺损模型评估MSC-CM在促进伤口愈合、再上皮化、毛囊和血管生成方面的功效。
体外试验表明,MSC-CM显著增强了HUVECs的功能,包括迁移和管形成。体内试验表明,MSC-CM在愈合速度、再上皮化、毛囊和血管生成方面表现出显著进展。
这些结果表明,MSC-CM可以促进糖尿病小鼠的伤口愈合,并使再生组织中的血管结构更稳定,而不会诱导组织纤维化,为治疗糖尿病皮肤伤口提供了一种新的治疗策略。这为再生医学和细胞治疗的进一步研究提供了有价值的理论基础。